- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Abbreviated New Drug Applications and 505(b)(2) Applications
First Quarter
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.
Reference Listed Drug | ANDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Hetlioz | Vanda | tasimelteon | Apotex | Used to treat non-24 hour sleep-wake disorder in adult patients and for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome in patients ≥16 years old. | 1/05/2024 |
Prolensa | Bausch & Lomb | bromfenac ophthalmic solution, 0.07% | Lupin | Used to treat postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. | 1/09/2024 |
Chantix | PF Prism | varenicline | Lupin | Used as an aid to smoking cessation treatment. | 1/10/2024 |
Chantix | PF Prism | varenicline | Apotex | Used as an aid to smoking cessation treatment. | 1/15/2024 |
Korlym | Corcept Therapeutics | mifepristone | Teva | Used to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type II diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. | 1/19/2024 |
Orfadin | Swedish Orphan | nitisinone | Eton | Used to treat hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. | 2/02/2024 |
Alphagan P Ophthalmic Solution | AbbVie | brimonidine tartrate | Alembic | Used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. | 2/06/2024 |
Invega | Janssen | paliperidone | Camber | Used to treat schizophrenia, schizoaffective disorder as monotherapy, and as an adjunct to mood stabilizers and/or antidepressants. | 2/12/2024 |
Entereg | Cubist | alvimopan | Hikma | Used to help restore normal bowel function in patients who have just had bowel resection surgery. | 2/13/2024 |
Pradaxa | Boehringer Ingelheim | dabigatran etexilate | Apotex | Used to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days, to reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated, for the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery. | 2/13/2024 |
Ganirelix Acetate | Organon | ganirelix acetate | Lupin | Used to inhibit premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. | 2/15/2024 |
BiCNU | Avent Lifesciences | carmustine | Alembic | Used alone or together with other medicines to treat certain type of brain tumors (e.g., glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors), cancer of the lymph system (e.g., Hodgkin's disease, non-Hodgkin's lymphoma), and a certain type of cancer in the bone marrow (e.g., multiple myeloma). | 2/21/2024 |
Cytoxan | Baxter | cyclophosphamide | Fresenius Kabi | Used to treat cancer of the ovaries, breast, blood and lymph system, and nerves (mainly in children). Also used for retinoblastoma (a type of eye cancer mainly in children), multiple myeloma (cancer in the bone marrow), and mycosis fungoides (tumors on the skin). | 2/28/2024 |
Trileptal | Novartis | oxcarbazepine | Camber | Used for adults as monotherapy or adjunctive therapy in the treatment of partial-onset seizures. Pediatrics use as monotherapy in the treatment of partial-onset seizures in children 4 to 16 years of age, and as adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years of age. |
2/29/2025 |
Lipitor | Pfizer | atorvastatin | Camber | Used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke. | 2/29/2024 |
Vascepa | Amarin | icosapent | Camber | Used as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalizing in adult patients with elevated triglycerides and established cardiovascular disease or who have diabetes mellitus and ≥2 other risk factors for cardiovascular disease. It is also indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. | 3/08/2024 |
Gralise | Chemo Research | gabapentin | Camber | Used to manage Postherpetic Neuralgia (PHN). | 3/18/2024 |
Theophylline | Bausch | theophylline | Camber | Used to treat symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases. | 3/20/2024 |
Duexis | Horizon Therapeutics | ibuprophen / famotidine | Endo | Used to relieve the signs and symptoms of rheumatoid arthritis and osteoarthritis while decreasing the risk of developing ulcers of the stomach and upper intestines people may experience from ibuprofen alone. | 3/26/2024 |
Zomig | IPR Pharmaceuticals | zolmitriptan | Alembic | Used for the acute treatment of migraine with or without aura in adults. | 3/28/2024 |
Zyloprim | Casper Pharma | allopurinol | Camber | Used to manage patients with signs and symptoms of primary or secondary gout, the management of patients with conditions requiring therapies which cause elevations of serum and urinary uric acid levels, and the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds specific thresholds. | 3/29/2024 |
GENERICally Speaking Hatch Waxman Bulletin
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.